GSE96649 belinostat A-549 1 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE96649_belinostat_A-549_1_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE96649_belinostat_A-549_1_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE96649_belinostat_A-549_1_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE96649_belinostat_A-549_1_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

acetylserotonin O-methyltransferase like

Gene

H2B clustered histone 8

Gene

H3.7 histone (putative)

Gene

BAIAP2 divergent transcript

Gene

metastasis associated lung adenocarcinoma transcript 1

Gene

lung cancer associated transcript 1

Gene

HERPUD2 antisense RNA 1

Gene

PRR34 antisense RNA 1

Gene

5-hydroxytryptamine receptor 7 pseudogene 1

Gene

IGFL2 antisense RNA 1

  • Gene

    acetylserotonin O-methyltransferase like


  • Gene

    H2B clustered histone 8


  • Gene

    H3.7 histone (putative)


  • Gene

    BAIAP2 divergent transcript


  • Gene

    metastasis associated lung adenocarcinoma transcript 1


  • Gene

    lung cancer associated transcript 1


  • Gene

    HERPUD2 antisense RNA 1


  • Gene

    PRR34 antisense RNA 1


  • Gene

    5-hydroxytryptamine receptor 7 pseudogene 1


  • Gene

    IGFL2 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.